Skip to Content
  • Opinion
  • Open Access

17 September 2024

10 Pages

Companion Tests and Personalized Cancer Therapy: Reaching a Glass Ceiling

,
,
and
1
Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d’Azur, 06189 Nice, France
2
FHU OncoAge, IHU RespirERA, IRCAN, Inserm, University Côte d’Azur, CNRS 7284, U1081, 06000 Nice, France
3
Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d’Azur, 06189 Nice, France
4
Oncopharmacology Unit, Centre Antoine Lacassagne, University Côte d’Azur, 06189 Nice, France
This article belongs to the Special Issue Precision Medicine in Oncology 2.0

Abstract

The use of companion diagnostics has become a standard in precision oncology in the context of ongoing therapeutic innovation. However, certain limitations make their application imperfect in current practice. This position paper underscores the need to broaden the notion of companion testing, considering the potential of emerging technologies, including computational biology, to overcome these limitations. This wave of progress should impact not only our representation of the analytical tool itself but also the nature of the tumoral sample under analysis (liquid biopsies). The complex inter-relationship between companion test guided-personalized therapy, and health agency policies for new drug agreements will also be discussed.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.